LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the completion of its Biologics License Application (BLA) submission ...

Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease that affects somewhere between 4 and 40 people per million worldwide. The condition causes substances such as fats and proteins ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the fourth quarter and fiscal year 2024, ...

Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

offering a simpler way to diagnose autoimmune pulmonary alveolar proteinosis or aPAP, using just a finger-prick blood sample. Autoimmune PAP is a rare lung disease caused by antibodies that ...

The sisters that Neehus studied had several lung abnormalities: a history of respiratory infections, polycystic lung disease, and pulmonary alveolar proteinosis (PAP), a disorder characterized by lung ...

Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Autoimmune pulmonary alveolar proteinosis is characterized by the accumulation of surfactant in the lungs, leading to difficulty in breathing and other severe symptoms. Current treatments are ...

for MOLBREEVI* as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP). If Priority Review is granted by the FDA, MOLBREEVI could potentially be approved by the end of the year.

In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with ...